Anastrozole (CAS 120511-73-1, ZD1033/Arimidex) is a leading nonsteroidal aromatase inhibitor API for postmenopausal hormone-positive breast cancer therapy. Our pharma-grade raw powder ≥99% HPLC purity is available from gram sample to bulk kg packing for pharmaceutical formulation and preclinical pharmacology research.
GMP factory supply Anastrozole Powder high purity CAS 120511-73-1 Anastrozole
| Item |
Details |
| Product Name |
Anastrozole |
| CAS No. |
120511-73-1 |
| Synonyms |
Arimidex, ZD1033, ICI-D1033 |
| Chemical Name |
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropiononitrile) |
| Molecular Formula |
C17H19N5 |
| Molecular Weight |
293.37 |
| MDL Number |
MFCD00866298 |
| ATC Code |
L02BG03 |
| Appearance |
White to off-white crystalline powder |
| Purity |
≥99.0% HPLC(USP/EP Pharma Grade) |
| Melting Point |
81~82℃ |
| Density |
1.08±0.1 g/cm³ |
| Solubility |
Freely soluble in acetonitrile,methanol,ethanol,DMSO(40mg/mL); Slightly soluble in water(0.53mg/mL,25℃) |
| Storage |
Sealed dry & away from light;Short-term: 15~25℃;Long-term: 2~8℃/-20℃ sealed |
| Mechanism |
Potent selective non-steroidal aromatase inhibitor, suppress aromatase activity to block peripheral synthesis, cut level for hormone-dependent tumor inhibition |
| Application |
1. Oral API for breast cancer tablet(1mg/tablet original Arimidex)
2. Clinical usage: Adjuvant & advanced-stage treatment for postmenopausal HR-positive breast cancer
3. Laboratory aromatase inhibitor research reagent |
| Standard |
USP, EP pharmacopoeia specification |
